7,352 Shares in HCA Healthcare, Inc. $HCA Acquired by Donoghue Forlines LLC

Donoghue Forlines LLC bought a new position in shares of HCA Healthcare, Inc. (NYSE:HCA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 7,352 shares of the company’s stock, valued at approximately $2,817,000.

Other institutional investors have also recently bought and sold shares of the company. Clearstead Trust LLC raised its position in shares of HCA Healthcare by 311.8% in the second quarter. Clearstead Trust LLC now owns 70 shares of the company’s stock valued at $27,000 after buying an additional 53 shares in the last quarter. MV Capital Management Inc. grew its holdings in shares of HCA Healthcare by 138.7% during the 2nd quarter. MV Capital Management Inc. now owns 475 shares of the company’s stock worth $182,000 after purchasing an additional 276 shares in the last quarter. D Orazio & Associates Inc. bought a new stake in HCA Healthcare during the second quarter worth about $201,000. Cherokee Insurance Co acquired a new position in shares of HCA Healthcare in the 2nd quarter valued at approximately $3,869,000. Finally, Candriam S.C.A. boosted its position in shares of HCA Healthcare by 3.2% during the 2nd quarter. Candriam S.C.A. now owns 161,640 shares of the company’s stock worth $61,927,000 after acquiring an additional 5,069 shares in the last quarter. Institutional investors own 62.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on HCA shares. Raymond James Financial set a $525.00 target price on HCA Healthcare in a report on Monday, October 27th. Wolfe Research cut shares of HCA Healthcare from an “outperform” rating to a “peer perform” rating in a research report on Monday, July 28th. JPMorgan Chase & Co. boosted their target price on shares of HCA Healthcare from $360.00 to $370.00 and gave the stock a “neutral” rating in a research note on Monday, August 4th. KeyCorp boosted their price objective on HCA Healthcare from $465.00 to $475.00 and gave the stock an “overweight” rating in a research report on Monday, October 27th. Finally, Jefferies Financial Group lifted their price target on HCA Healthcare from $485.00 to $525.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $474.53.

Insider Buying and Selling at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 3,836 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the sale, the executive vice president owned 31,503 shares in the company, valued at $13,194,716.52. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Michael R. Mcalevey sold 3,892 shares of the company’s stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total transaction of $1,843,990.68. Following the transaction, the executive vice president owned 3,487 shares in the company, valued at approximately $1,652,105.73. The trade was a 52.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.30% of the company’s stock.

HCA Healthcare Price Performance

Shares of HCA opened at $473.42 on Friday. The business has a 50-day moving average of $432.52 and a 200-day moving average of $395.09. HCA Healthcare, Inc. has a 1 year low of $289.98 and a 1 year high of $479.43. The company has a market capitalization of $108.03 billion, a price-to-earnings ratio of 18.30, a price-to-earnings-growth ratio of 1.38 and a beta of 1.41.

HCA Healthcare (NYSE:HCA) last announced its earnings results on Friday, October 24th. The company reported $6.96 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $1.32. HCA Healthcare had a net margin of 8.53% and a negative return on equity of 792.25%. The business had revenue of $19.16 billion during the quarter, compared to the consensus estimate of $18.55 billion. During the same quarter last year, the firm earned $4.90 earnings per share. HCA Healthcare’s quarterly revenue was up 9.6% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. As a group, sell-side analysts anticipate that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 29th. Investors of record on Monday, December 15th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, December 15th. HCA Healthcare’s payout ratio is presently 11.13%.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.